AbbVie has made major headlines in the pharmaceutical sector through its aggressive strategic expansions, most notably entering into a definitive agreement to acquire clinical-stage biotech firm Apogee Therapeutics for approximately $10.9 billion. This major corporate buyout is designed to fortify AbbVie's world-class immunology portfolio, secure next-generation therapies, and offset future revenue impacts from looming patent expirations on legacy blockbusters.